Significance of serum concentrations of proand anti-inflammatory cytokines in identification of patients with Crohn's disease;Znaczenie surowiczych stȩżeń cytokin proi przeciwzapalnych w identyfikacji chorych na chorobȩ Crohna

Polski Merkuriusz Lekarski

Volumn 29, Issue 171, 2010, Pages 169-172

  Kohut, Maciej ^a   Hartleb, Marek ^a   Hartleb, Teresa ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

C reactive protein; Crohn's disease; Cytokines

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CROHN DISEASE; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77957912251     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Armitage P.: Melody statystyczne w badaniach medycznych. PZWL, Warszawa 1978.
2. Brown R. A., Swanson-BeckJ.: Medical statistics on microcomputers. BMJ Publisher Group, London 1992.
3. Cassini-Raggi V., Kam L., Chong Y. J. T.: Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. J. Immunol., 1995, 154, 2434-2440.
4. Costa F., Mumolo M. G., Ceccarelli L. I wsp.: Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut, 2005, 54 (3), 364-368.
5. Filik L., Dagli U., Ulker A.: C-reactive protein and monitoring the activity of Crohn's disease. Adv. Ther., 2006, 23, 655-662.
6. Gardiner K. R., Halliday M. I., Barclay G. R.: Significance of systemic endotoxaemia in inflammatory bowel disease. Gut, 1995, 36, 897-901.
7. Gisbert J. P., Gonzalez-Lama Y., Mate J.: Role of biological markers in inflammatory bowel disease. Gastroenterol. Hepatol., 2007, 30, 117-129.
8. Grzybowska-Chlebowczyk U., Woś H., Gabryel B., Wiȩcek S., Kajor M., Paja̧k J.: Ocena stȩżefi TNF-a w surowicy dzieci z nieswoistymi zapaleniami jelit. Przegiad Gastroenterol., 2008, 3, 149-153.
9. Hadziselimovic R: Urinary excretion of TNF receptors. Gut, 1996, 38, 153-154.
10. Hadziselimovic F., Emmons L. R., Gallati H.: Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and efficacy of treatment of inflammatory bowel disease. Gut, 1995, 37, 260-263.
11. Hyams J., Treem W., Eddy E.: Tumor necrosis factor is not elevated in children with inflammatory bowel disease. J. Pediatr. Gastroenterol., 1991, 12, 233-236.
12. Jones J., Loftus E. V. Jr., Pannacione R., Chen L. S., Peterson S.: Relationship between disease activity and fecal biomarkers in patients with Crohn's disease. Clin. Gastroenterol. Hepatol., 2008, 6, 1218-1224.
13. Karoul S., Ouerdiane S., Serghini M., Jomn., Kallel L., Fekih M.: Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Dig. Liver Dis., 2007, 39 (11), 1006-1010.
14. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., MIchalsen A., Dobos G. J.: Noninvasive markers in the assessment of intestinal inflammation in IBD: performance of fecal lactoferrin, calprotectin and PMN-elastase, CRP and clinical indices. Am. J. Gastroenterol., 2008, 103, 162-169.
15. Limburg P. J., Devens M. E., Harrington J. J., Diehl N. N., Mahoney D. W., Ahlquist DA.: Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am. J. Gastroenterol., 2003, 98 (10), 2299-2305.
16. Ling P. R., Schwartz J. H., Jeevanandam M.: Metabolic changes in rats during a continuous infusion of recombinant interleukin-1. Am. J. Physiol., 1996, 270, E305-312.
17. Lopez Morante A. J., Saez-Royuela F., Yuguero del Moral L., Martin Lorente J. L., Ojeda Gimenez C.: The usefulness of reactive protein C in managing patients with ulcerative colitis and Crohn's disease. Rev. Esp. Enferm. Dig., 1993, 83, 5-9.
18. MacDonald T. T., Hutchings P., Choy M. Y.: Tumor necrosis factor and Interferon-gamma production measured at single cell level in normal and inflamed human intestine. Clin. Exp. Immunol., 1990, 81, 301-305.
19. Maeda M., Watanabe N., Neda H.: Serum TNF-α activity in inflammatory bowel disease. Immunopharmacol. Immunotoxicol., 1992, 14, 451-461.
20. Mahida Y. R., Kurlac L., Gallagher A.: High circulating concentrations of IL-6 in active Crohn's disease but not ulcerative colitis. Gut, 1992, 32, 1531-1534.
21. Mazlam M. Z., Hodgson H. J. F.: Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut, 1992, 33, 773-778.
22. Niederau C., Backmerhoff F., Schumacher B.: Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology, 1997, 44, 90-107.
23. Nielsen O. H., Brynskov J., Bendtzen K.: Circulating and mucosal concentrations of TNF and inhibitors in chronic inflammatory bowel disease. Dan. Med. Bull., 1993, 40, 247-249.
24. Nielsen O. H., Vainer B., Madsen S. M., Seidelin J. B., Heegaard N. H.: Established and emerging biological activity markers of Inflammatory bowel disease. Am. J. Gastroenterol., 2000, 95, 359-367.
25. Olson A. D., Ayass M., Chensue S.: Tumor necrosis factor and IL-1β expression in pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr., 1993, 16, 241-246.
26. Rodgers A. D., Cummins A. G.: CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig. Dis. Sci., 2007, 52, 2063-2068.
27. Saiki T., Mitsuyama K., Toyanaga A.: Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J. Gastroenterol., 1998, 33, 616-622.
28. Sategna-Guidetti C., Pulitano R., Fenogli L.: Tumor necrosis factor/cachectin in Crohn's disease. Relation of serum concentration to disease activity. Recenti. Prog. Med., 1993, 84, 93-99.
29. Schoepfer A. M., Trummler M., Seeholzer P., Seibold-Schmid B., Seibold F.: Discriminating IBD from IBS: comparison of he performance of fecal markers, blood leukocytes, CRP and IBD abtibodies. Inflamm. Bowel Dis., 2008, 14 (1), 32-39.
30. Shine B., Berghouse L., Jones J. E., Landon J.: C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin. Chim. Acta, 1985, 148, 105-109.
31. Sipponen T., Savilahti E., Kolho K. L., Nuutinen H., Turunen U., Farkkila M.: Crohn's disease activity assessed by fecal calprotectin and lactoferin: correlation with CDAI and endoscopic findings. Inflamm. Bowel Dis., 2008, 14, 40-46.
32. Solem C. A., Loftus E. V. Jr., Tremaine W. J., Harmsen W. S.: Con-elation of CRP with clinical, endoscopic, histologic and radiographic activity in inflammatory bowel disease. Inflamm. Bowel Dis., 2005, 11 (8), 707-712.
33. Sostegni R., Daperno M., Scaglione N., Lavagna A., Rocca R., Pera A.: Crohn's disease: monitoring disease activity. Aliment. Pharmacol. Ther., 2003, 2, 11-17.
34. Stronkhorst A. Jansen J., Tytgat G.: Soluble IL-2 anf TNF receptors p55 and p75 in Crohn's disease. Gastroenterology, 1994, 106, A779.
35. Sugi K., Saitoh O., Hirata I.: Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophilderived proteins. Am. J. Gastroenterol., 1996, 91, 927-934.
36. Van Dullemen H. M., van Deventer S. J., Hommes D. W.: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibodies (aA2). Gastroenterology, 1995, 109, 129-135.
37. Vermeire S., van Assche G., Rutgeerts P.: C-reactive protein as a marker for inflammatory bowel disease. Inflamm. Bowel Dis., 2004, 10 (5), 661-665. (Pubitemid 39276479)
38. Vermeire S., van Assche G., Rutgeerts P.: Laboratory markers in IBD: useful, magic or unnecessary toys? Gut, 2006, 55 (3), 426-431.
39. Yamamoto T., Umegae S., Kitagawa T., Matsumoto K.: Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse. Aliment. Pharmacol. Ther., 2004, 19, 671-678.